NASDAQ:ACLX

Arcellx (ACLX) Stock Forecast, Price & News

$44.15

+0.48 (+1.10%)

(As of 05/31/2023 ET)

Compare

Today's Range: $43.49
▼
$45.66
50-Day Range: $27.49
▼
$46.90
52-Week Range: $11.55
▼
$48.92

Volume: 869,345 shs
Average Volume: 476,672 shs
Market Capitalization: $2.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.38

Arcellx MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 14.1% Upside
$50.38 Price Target
Short Interest: Bearish
22.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 6 Articles This Week
Insider Trading: Selling Shares
$76.34 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.20) to ($2.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

886th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

145th out of 167 stocks

3.5

Analyst's Opinion

Consensus Rating
Arcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.38, Arcellx has a forecasted upside of 14.1% from its current price of $44.15.
Amount of Analyst Coverage
Arcellx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
22.12% of the float of Arcellx has been sold short.
Short Interest Ratio / Days to Cover
Arcellx has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Arcellx has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Arcellx does not currently pay a dividend.
Dividend Growth
Arcellx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACLX.

2.0

News and Social Media Coverage

News Sentiment
Arcellx has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Arcellx this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,338,911.00 in company stock.
Percentage Held by Institutions
91.78% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arcellx are expected to decrease in the coming year, from ($1.20) to ($2.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcellx is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcellx is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcellx has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Stock News Headlines

May 28, 2023 | sg.finance.yahoo.com

Arcellx, Inc. (ACLX) stock price, news, quote & history – Yahoo Finance

May 28, 2023 | americanbankingnews.com

Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) CFO Sells $369,571.84 in Stock

May 31, 2023 | Behind the Markets (Ad)

"The $51 Billion Laser Revolution"

See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>

May 21, 2023 | americanbankingnews.com

Arcellx (NASDAQ:ACLX) Research Coverage Started at Truist Financial

May 18, 2023 | msn.com

The Latest Analyst Ratings for Arcellx

May 18, 2023 | msn.com

Truist Securities Initiates Coverage of Arcellx (ACLX) with Buy Recommendation

May 17, 2023 | americanbankingnews.com

Sr One Capital Management, Llc Sells 1,012,833 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock

May 17, 2023 | americanbankingnews.com

Jill Carroll Sells 638,417 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock

May 31, 2023 | Behind the Markets (Ad)

WARNING TO ALL U.S. INVESTORS

May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>

May 17, 2023 | americanbankingnews.com

Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update

May 16, 2023 | markets.businessinsider.com

Arcellx Inc (ACLX) Receives a Buy from Stifel Nicolaus

May 16, 2023 | americanbankingnews.com

Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Recommendation of "Buy" from Analysts

May 14, 2023 | americanbankingnews.com

Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $22,500.00 in Stock

May 13, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for Arcellx, Inc. Issued By William Blair (NASDAQ:ACLX)

May 13, 2023 | americanbankingnews.com

HC Wainwright Comments on Arcellx, Inc.'s Q2 2023 Earnings (NASDAQ:ACLX)

May 12, 2023 | msn.com

B of A Securities Maintains Arcellx (ACLX) Buy Recommendation

May 12, 2023 | americanbankingnews.com

Needham & Company LLC Boosts Arcellx (NASDAQ:ACLX) Price Target to $51.00

May 11, 2023 | americanbankingnews.com

Arcellx (NASDAQ:ACLX) Price Target Increased to $50.00 by Analysts at Bank of America

May 11, 2023 | americanbankingnews.com

Arcellx (NASDAQ:ACLX) Price Target Raised to $49.00 at HC Wainwright

May 10, 2023 | finance.yahoo.com

Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 10, 2023 | americanbankingnews.com

Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) Insider Sells 1,200 Shares of Stock

May 10, 2023 | marketwatch.com

8-K: Arcellx, Inc.

May 9, 2023 | msn.com

Barclays Maintains Arcellx (ACLX) Overweight Recommendation

May 9, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Arcellx Inc (ACLX)

May 9, 2023 | msn.com

HC Wainwright & Co. Maintains Arcellx (ACLX) Buy Recommendation

May 9, 2023 | americanbankingnews.com

Barclays Boosts Arcellx (NASDAQ:ACLX) Price Target to $49.00

May 8, 2023 | finance.yahoo.com

Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings: 3/29/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACLX
CUSIP: N/A
CIK: 1786205
Web: arcellx.com
Phone: 240-327-0603
Fax: N/A
Employees: 78
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $50.38
High Stock Price Forecast: $104.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +11.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-188,680,000.00
Net Margins: N/A
Pretax Margin: -1,058.80%
Return on Equity: -47.99%
Return on Assets: -31.10%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 3.44
Quick Ratio: 3.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.33 per share
Price / Book: 7.15

Miscellaneous

Outstanding Shares: 48,000,000
Free Float: N/A
Market Cap: $2.17 billion
Optionable: Not Optionable
Beta: -0.33

Key Executives

Mr. Rami Elghandour (Age 44)
Chairman, CEO & Pres
Comp: $803.97k

Mr. Neeraj P. Teotia (Age 48)
Chief Commercial Officer
Comp: $461.95k

Dr. Christopher R. Heery M.D. (Age 43)
Chief Medical Officer
Comp: $629.92k

Ms. Michelle Lim Gilson (Age 31)
Chief Financial Officer

Mr. Michael Dombeck M.B.A.
Chief Operating Officer

Mr. Narinderjeet Singh M.S. (Age 51)
Chief Technical Officer

Mr. David Tice Ph.D. (Age 52)
Chief Scientific Officer

Ms. Myesha Lacy
VP of Investor Relations

Ms. Maryam Abdul-Kareem J.D.
M.S., Gen. Counsel

Ms. Kate Aiken
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings or view top-rated stocks.
What is Arcellx's stock price forecast for 2023?: 11 brokers have issued 12 month target prices for Arcellx's stock. Their ACLX share price forecasts range from $34.00 to $104.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts.
How have ACLX shares performed in 2023?: Arcellx's stock was trading at $30.98 at the beginning of the year. Since then, ACLX stock has increased by 46.2% and is now trading at $45.28.
View the best growth stocks for 2023 here.
When is Arcellx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ACLX earnings forecast.
How were Arcellx's earnings last quarter?: Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.05.
What ETFs hold Arcellx's stock?: ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

When did Arcellx IPO?: (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.
What is Arcellx's stock symbol?: Arcellx trades on the NASDAQ under the ticker symbol "ACLX."
Who are Arcellx's major shareholders?: Arcellx's stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.00%), FMR LLC (5.61%), Suvretta Capital Management LLC (5.00%), BlackRock Inc. (4.64%), State Street Corp (3.91%) and Pictet Asset Management SA (2.15%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Scott D Sandell and Sr One Capital Management, Llc.
View institutional ownership trends.
How do I buy shares of Arcellx?: Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arcellx's stock price today?: One share of ACLX stock can currently be purchased for approximately $45.28.
How much money does Arcellx make?: Arcellx (NASDAQ:ACLX) has a market capitalization of $2.17 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($4.34) on an earnings per share basis.
How can I contact Arcellx?: The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arcellx (ACLX) Stock Forecast, Price & News

Arcellx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Arcellx (NASDAQ:ACLX) Stock

ACLX Stock News Headlines

ACLX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACLX Stock - Frequently Asked Questions

Overall MarketRank^™